Business
PTX-200 High Overall Response in Ph2a Breast Cancer trial
PTX-200 High Overall Response in Ph2a Breast Cancer trial
About this update from Prescient Therapeutics Limited
[{"type":"text","content":"Prescient Therapeutics Ltd has released a press release. View Attachment","length":254,"tagName":"div"}]